Oing CDepartment of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Giannatempo PDepartment of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Honecker FZeTuP Breast and Tumor Center, St. Gallen, Switzerland.
Oechsle KDepartment of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bokemeyer CDepartment of Oncology, Hematology and Bone Marrow Transplantation with Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Beyer JDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3031 Bern, Switzerland. Electronic address: joerg.beyer@insel.ch.
English
Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.